Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 22;104(5):973–985. doi: 10.3324/haematol.2018.199661

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 7. — CD147 gene expression level does not predict overall survival in acute myeloid leukemia (AML), but is correlated in early death of (non-M3)-AML patients. (A) Relationship between the most recurrent gene mutations observed in all AMLs and the level of CD147 mRNA expression, according to the TCGA dataset. (B) CD147 mRNA levels were analyzed in AMLs stratified into 3 risk groups: poor, intermediate and favorable, according to the European LeukemiaNet (ENL) risk classification. (C) Kaplan-Meier survival analysis in a new group of AML patients that excludes AML-M3 patients, based on CD147 gene expression and stratified according to their CD147 mRNA levels in 3 groups: low (CD147<70); medium (CD147, range, 70-120); high (CD147 >120). (D) Kaplan-Meier survival analysis in the new group of (non-M3)-AML patients deceased within 50-60 months years after diagnosis, indicates that the kinetics of death is more rapid (within 20 months) among CD147 high patients, as compared with those with low (P<0.01) or medium (P<0.001) CD147 levels; P-values calculated by log-rank test. The histograms show that white blood count (WBC) number, age at diagnosis and proportion of patients with poor cytogenetics were comparable in the 3 (non-M3)-AML subgroups subdivided according to CD147 expression level.